ARTEMIs

Team: Ahmed Ba-Ssalamah, Georg Langs, Daniel Sobotka, Alexander Herold, Philipp Seeböck

ARTEMIs Aims

ARTEMIs was launched on the 1st of January 2024 with the aim of making a major leap forward in the management of MAFLD. The leading cause of chronic liver disease (CLD) in Europe surpassing viral hepatitis and alcohol-related causes.

ARTEMIs´ approach aims to control this fast-growing metabolic syndrome and its complications by leveraging advanced liver and heart Virtual Twins. For this purpose, the project will co-design, develop, and evaluate a clinical decision support system (CDSS) for application in the clinical management of MAFLD patients.

To advance knowledge in this field, the European Union (EU), through the Horizon Europe

(HE) programme, will invest 10 million euros in ARTEMIs over the next 4 years. Thanks to this EU-funded project, a powerful tool to help decision-making towards improved patient management strategies, personalized diagnostics, and innovative therapeutic strategies will be developed. ARTEMIs has the ambition to enable early disease detection, prediction of disease progression, and effective disease management. This will ultimately contribute to promoting Real-World Data and AI for secure and ethical decision-making in healthcare in alignment with some of the most ambitious EU goals in terms of healthcare digitalization in the coming years.

CIR in ARTEMIs

The CIR team will conduct research in machine learning based models of fatty liver disease, linking cutting edge imaging data and clinical variables of patients. The research aims at bridging data driven approaches that enable the integration of observations from large numbers of patients with simulation models and mechanistic explanations of disease and treatment response. 

ARTEMIs Consortium Partners

AP-HP (Henri Mondor, Paul Brousse, and Pitié Salpêtrière Hospitals), Betthera, Bournemouth University, Charité, Cliniques Universitaires Saint-Luc, German Cancer Research Center (DKFZ), European Liver Patients' Association (ELPA), Heidelberg University Hospital, Imperial College Healthcare (NHS trust), National Institute for Research in Digital Science and Technology (INRIA), Institute of Cardiometabolism and Nutrition (ICAN), Jena University Hospital, La Fe Health Research Institute, Leipzig University, Matical, Medical University of Vienna, Medexprim, Sapienza University of Rome, Sant'Andrea University Hospital, Sheba Medical Center, Vall d'Hebron Research Institute.

Link to project website: https://www.linkedin.com/company/artemis-the-power-of-virtual-twines-to-fight-mafld